Abstract P4-21-03: A randomized phase II study of Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer

Mapping Intimacies ◽

10.1158/1538-7445.sabcs16-p4-21-03 ◽

2017 ◽

Author(s):

M Takahashi ◽

Y Nishiyama ◽

F Hara ◽

Y Naito ◽

M Baba ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preoperative Chemotherapy ◽

Phase Ii Study ◽

Her2 Positive ◽

Ki 67 ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Ki-67 Index Guided Selection of Preoperative Chemotherapy for HER2-positive Breast Cancer: A Randomized Phase II Trial

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hys161 ◽

2012 ◽

Vol 42 (12) ◽

pp. 1211-1214 ◽

Author(s):

T. Yamaguchi ◽

H. Mukai

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preoperative Chemotherapy ◽

Phase Ii Trial ◽

Her2 Positive ◽

Ki 67 ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Selection Of ◽

Positive Breast Cancer

Download Full-text

S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC).

10.1158/0008-5472.sabcs11-s5-1 ◽

2011 ◽

Author(s):

L Gianni ◽

G Bianchini ◽

A Kiermaier ◽

G Bianchi ◽

Y-H Im ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

10.1158/1538-7445.sabcs19-gs1-05 ◽

2020 ◽

Author(s):

Sara M Tolaney ◽

Lorenzo Trippa ◽

William Barry ◽

Jiani Hu ◽

Chau Dang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Stage I ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

5149 Randomized phase II trial of preoperative chemotherapy plus lapatinib, trastuzumab or both in HER2 positive breast cancer: results of the first step simon's design

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71041-9 ◽

2009 ◽

Vol 7 (2) ◽

pp. 304

Author(s):

V. Guarneri ◽

A. Frassoldati ◽

A. Bottini ◽

K. Cagossi ◽

L. Cavanna ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preoperative Chemotherapy ◽

Phase Ii Trial ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Randomized Phase II Study of Primary Systemic Chemotherapy and Trastuzumab for Operable HER2 Positive Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2011.10.002 ◽

2012 ◽

Vol 12 (1) ◽

pp. 49-56 ◽

Author(s):

Seigo Nakamura ◽

Masashi Ando ◽

Norikazu Masuda ◽

Kenjiro Aogi ◽

Hiroyo Ino ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Systemic Chemotherapy ◽

Phase Ii Study ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Primary Systemic Chemotherapy ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

Journal of Neuro-Oncology ◽

10.1007/s11060-011-0629-y ◽

2011 ◽

Vol 105 (3) ◽

pp. 613-620 ◽

Author(s):

Nancy U. Lin ◽

Wolfgang Eierman ◽

Richard Greil ◽

Mario Campone ◽

Bella Kaufman ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Breast Cancer Brain Metastases ◽

Positive Breast Cancer

Download Full-text

A multicenter, randomized phase II study of neoadjuvant chemotherapy including trastuzumab with cyclophosphamide with docetaxel in patients with operable HER2-positive breast cancer (JBCRG-10 study).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps105 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS105-TPS105

Author(s):

N. Masuda ◽

M. Toi ◽

T. Ueno ◽

K. Aogi ◽

H. Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.724195112.793501041 ◽

2014 ◽

Author(s):

Minesh Mehta ◽

Manmeet Ahluwalia

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Multicenter Phase ◽

Positive Breast Cancer

Download Full-text

All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer – A phase II study

Journal of the Egyptian National Cancer Institute ◽

10.1016/j.jnci.2014.08.001 ◽

2014 ◽

Vol 26 (4) ◽

pp. 187-194 ◽

Author(s):

Hanan Shawky ◽

Hesham Tawfik

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text

Abstract OT1-1-09: Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER2-positive breast cancer.

10.1158/0008-5472.sabcs12-ot1-1-09 ◽

2012 ◽

Author(s):

J Gavilá ◽

A Llombart ◽

A Guerrero ◽

A Ruiz ◽

V Guillem

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Liposomal Doxorubicin ◽

Phase Ii Study ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Download Full-text